CN100400545C - Method for preparing phosphate eritrocina using eritrocina salt - Google Patents
Method for preparing phosphate eritrocina using eritrocina salt Download PDFInfo
- Publication number
- CN100400545C CN100400545C CNB2006100417585A CN200610041758A CN100400545C CN 100400545 C CN100400545 C CN 100400545C CN B2006100417585 A CNB2006100417585 A CN B2006100417585A CN 200610041758 A CN200610041758 A CN 200610041758A CN 100400545 C CN100400545 C CN 100400545C
- Authority
- CN
- China
- Prior art keywords
- erythromycin
- phosphoric acid
- salt
- solution
- prepare
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Saccharide Compounds (AREA)
Abstract
The present invention relates to a preparation method of a novel erythrocin salt, particularly to a method for using the erythrocin salt to prepare phosphoric acid erythrocin. The present invention is characterized in that the erythrocin salt is placed in an organic solvent of which C4-C6 comprises a hydroxy group or a carbonyl group and an organic solvent of a mixture, watering and stirring are carried out, pH values are adjusted by the addition of an alkali solution, the temperature of conversion extraction is controlled, the erythrocin salt is completely dissolved in an organic phase in the mode of stirring, and then a water phase is divided. A phosphoric acid solution is added in the organic phase, the pH values are adjusted in the mode of the continuous dropping of the phosphoric acid solution, and a crystallization reaction is carried out through the control on the concentration of the phosphoric acid solution and the temperature of the organic phase of erythrocin. Watering and purification are carried out, and finally, after separation and drying are carried out, the finished product of the phosphoric acid erythrocin is obtained. The present invention has the advantages of advanced process, little pollution to environment, low cost, simple preparation method and high benefit.
Description
Technical field
The present invention relates to a kind of preparation method of novel erythromycin salt, particularly about a kind of method for preparing phosphoric acid erythromycin with erythromycin salt.
Background technology
Phosphoric acid erythromycin is the phosphoric acid salt of erythromycin, is a kind of novel veterinary drug that just uses in recent years.It is consistent with Matachrom, Stellamicina, erythromycin estolate, the effect of erythromycin acetic ester, and drug effect and erythromycin are suitable, is mainly used in the treatment of inflammation in the animal body.Erythromycin and derivative thereof are at clinical application Macrolide Broad spectrum antibiotics very widely, and gram-positive microorganism is had the strong antibiotic effect.Be used for the infection that responsive gram-positive cocci causes.Antibacterial mechanisms is by combine the displacement of blocking-up transpeptidation and mRNA with the ribosomal 50S subunit of the bacterium of sensitivity.Suppress the synthetic of bacterioprotein and bring into play antibacterial or germicidal action.Phosphoric acid erythromycin is mainly used in control fowl chronic respiratory tract disease, infective rhinitis, enteritis, diarrhea, staphylococcus, streptococcal infection etc. as veterinary drug.That can also prevent and treat that environmental change causes stress.Phosphoric acid erythromycin is water-soluble, is choice drug to the diseases such as rotted gill disease, erythroderma and enteritis of fish, eel, and common diseases such as soft-shelled turtle, shrimp are had remarkable prevention effect.By clinical study repeatedly, phosphoric acid erythromycin is obtained significant curative effect in the intravital treatment of animals such as pony, fish.The effect of phosphoric acid erythromycin is consistent with erythromycin, but the advantage of its maximum is water-soluble all good than erythromycin, Matachrom, and oral animal absorbs good, again can injection for intravenous.Because erythromycin is 14 membered macrolide class alkaline antibiotics, be alkaline glycosides by erythromycin lactone is sugared with the deoxidation base and red mould sugared condensation forms.There are a plurality of hydroxyls in the structure, the hydroxyl reaction of the ketone group of C-9 position and C-12 and C-6 in the erythromycin under acidic conditions, alkene ether in generating, and then be condensed into keto-lactol.The erythromycin acidifying is carried out under acidic conditions just, so erythromycin can form salt with the various acid with certain acid number (comprising organic acid, mineral acid or acid salt).
The patent that U.S. US3276956 discloses a kind of " infection that the erythromycin for treating poultry is caused because of class pleuropneumonia germ ", its technology one adopts in the 340g 0.46mol erythromycin dissolving 500ml methyl alcohol, and to produce in the solution, dropwise add 52g 0.52mol and contain 85% phosphate aqueous solution, stir through brute force, filter reaction mixture, and this filtration product is done in spray, obtain the white solid of phosphoric acid erythromycin, fusing point is 145 ℃.But methyl alcohol is as the organic solvent of erythromycin, and toxicity is big, and volatility is big, and is unfavorable to environment protection, big to human body harm.Technology two adopts 40g (0.054mol) erythromycin is suspended in the 500ml water, and slowly adds the aqueous solution of 10% phosphoric acid of equimolar amount, the powerful stirring, and pH reaches 6.0 up to reaction mixture.The solution that generates obtains amorphous white solid of phosphoric acid erythromycin through freeze-drying, and fusing point is 145 ℃.Solubilized 5g this product in the water of every 100ml.But this technology obtains phosphoric acid erythromycin weight yield and activeconstituents is lower.European patent RU2190410 discloses a kind of patent of phosphoric acid erythromycin injection, its process using: in the time of 4～7 ℃, and with the aqueous suspension of erythromycin, through the acidifying of ortho-phosphoric acid solution, 5% one-tenth piece, the pH value of solution that obtains reaches 6.4～6.6.At 30～35 ℃, phosphoric acid erythromycin solution through sterile filtration, freeze-drying, is progressively raise the thermal barrier temperature 20 ℃ to 60 ℃, the deeper vacuum drying, but take this technology, easily separate out crystal in the reaction process, operation is also difficult.Through data at home and abroad investigation, phosphoric acid erythromycin has the report except that pharmacokinetic studies in animal body in recent years, and market, process aspect be report not almost.But the advantage of phosphoric acid erythromycin is water-soluble all good than erythromycin, Matachrom, and animal absorbs good, simultaneously can also intravenous injection.Predict that it has big potentiality in veterinary drug market.
Summary of the invention
The purpose of this invention is to provide and a kind ofly prepare the method for phosphoric acid erythromycin with erythromycin salt, its technology advanced person, environmental pollution is little, and cost is low, and the preparation method is simple, high efficiency.
Technical scheme of the present invention is, provides a kind of and prepares the method for phosphoric acid erythromycin with erythromycin salt, it is characterized in that: erythromycin salt is placed C
4-C
6Contain in the organic solvent of organic solvent and composition thereof of hydroxyl or carbonyl, add water, stir, add alkaline solution and regulate the pH value, control transforms extraction temperature, through stirring erythromycin salt is dissolved in the organic phase fully, divides the phase of anhydrating then, in organic phase, add phosphoric acid solution, regulate the pH value with the mode of continuous dropping phosphoric acid solution, carry out crystallization reaction by control phosphoric acid solution concentration with erythromycin organic phase temperature of reaction, add crystal's system, finally after separating drying, obtain phosphoric acid erythromycin finished product.
Described erythromycin salt is an erythromycin lactate, Matachrom.
Described C
4-C
6The organic solvent that contains hydroxyl or carbonyl is a n-butyl acetate, isobutyl acetate; The organic solvent of described mixture is the compounded organic solvent of propyl carbinol, n-butyl acetate and mibk.
The preparation of described phosphoric acid solution is to prepare with the phosphoric acid solvent identical with reaction medium, and concentration of phosphoric acid is 15%～60%; Reaction medium is the C that erythromycin is dissolved in
4-C
6A kind of or the water that contains the organic solvent of hydroxyl, carbonyl.
Described adding alkaline solution is regulated and transformed extraction pH value is 8～13, and described conversion extraction temperature remains on 10 ℃～30 ℃.
Described erythromycin salt is (weight/volume) 1: 15～20 with the ratio of organic solvent; Described erythromycin salt is (weight/volume) 1: 1～5 with the ratio of water.
Described control phosphoric acid solution concentration and with erythromycin organic phase temperature of reaction be 10 ℃～50 ℃.
Described its terminal point of phosphoric acid erythromycin finished product pH is 4～5.8.
Described alkaline solution is a salt of wormwood, yellow soda ash, potassium hydroxide, the aqueous solution of sodium hydroxide.
Characteristics of the present invention are: prepare phosphoric acid erythromycin with erythromycin salt, simplified production technique like this, cost reduces.Be the technical process shortening with difference with preparing phosphate eritrocina erythromycin maximum, use Matachrom to be starting raw material, omitted with erythromycin salt and transformed, crystallize into erythromycin, omitted the erythromycin drying, mix, pack supervisor, shorten schedule of operation, simplified operation, saved starting material power and manually waited cost, made production cost reduce, and saved the energy.The present invention prepares phosphoric acid erythromycin with the erythromycin salt starting raw material, with compare cost with the method for preparing phosphate eritrocina erythromycin and obviously reduce, present world market erythromycin price is about 580 yuan/kilogram (containing tax), and Matachrom only is about 340 yuan/kilogram (containing tax); With erythromycin is that starting raw material prepares phosphoric acid erythromycin, and phosphoric acid erythromycin quality is good, but the raw materials cost height, two kinds of preparation methods respectively have superiority.Compare process using organic solvent N-BUTYL ACETATE of the present invention, isobutyl acetate and double solvents with the patent US3276956 of the U.S. and substituted methyl alcohol, advantage is that toxicity is little.Methyl alcohol is second kind solvent, solvent for the restriction use, residual permission limit is 0.3% (seeing 2005 editions appendix P56 of Chinese Pharmacopoeia subordinate list 1), methyl alcohol has stronger toxicity, neural system and blood system to human body have the greatest impact, and it is taken in all and can react by toxigenicity through digestive tube, respiratory tract or skin; Organic solvents such as n-butyl acetate belong to the 3rd kind solvent, residual permission limit is 0.5% (seeing 2005 editions appendix P56 of Chinese Pharmacopoeia subordinate list 1), n-butyl acetate is good organic solvent and extraction agent, and n-butyl acetate belongs to the secondary inflammable liquid, little toxicant.With respect to organic solvent methyl alcohol, organic solvents such as making phosphoric acid erythromycin employing n-butyl acetate reduce the pollution of environment, to the injury minimizing of human body, and have reduced production cost.Phosphoric acid erythromycin weight yield and the activeconstituents of taking the present invention to prepare are higher, and simple to operate.
Transform the extraction temperature scope and transform extraction liquid pH scope, erythromycin salt can be dissolved in the organic phase fully, guarantee that erythromycin unit is not destroyed, improve the weight yield of phosphoric acid erythromycin; The effect of control phosphoric acid solution concentration is, is convenient to controls reaction speed, and processing ease is carried out, and is difficult for local overacidification; Range of reaction temperature can in time carry out reaction, is difficult for separating out crystal in the reaction process; Terminal point pH scope guarantees the activeconstituents maximum of phosphoric acid erythromycin, and the weight yield of phosphoric acid erythromycin is higher.
The present invention is by selecting different conversion extraction liquid pH scopes, transform the extraction temperature scope, different salt-forming reaction temperature ranges, control phosphoric acid solution concentration and terminal point pH scope, and the combination of these different parameters, can obtain different weight yields and activeconstituents.
Below the present invention will be further described by the present invention and U.S. Pat 3276956 and European patent RU2190410 test contrast.
By U.S. Pat 3276956 embodiment 1, adopt methyl alcohol as reaction medium, the phosphoric acid with 85% carries out acidification reaction, filter this solution after, spray is done, and obtains phosphoric acid erythromycin white powder.
Experimental phenomena: drip in the phosphatase reaction process, local overacidification very easily occurs, be difficult for stirring, during terminal point, very easily destroy activeconstituents, not easy to operate.Experimental data sees Table one.
Table one:
| Phosphoric acid concentration % | Weight yield % | Activeconstituents u/mg | Moisture % | Residue % | Residual solvent % |
| 85 | 74.8 | 770/811 | 5.1 | 2.2 | 0.1 |
By U.S. Pat 3276956 embodiment 2, as reaction medium, the phosphoric acid with 10% carries out acidification reaction with water.Experimental data sees Table two.
Experimental phenomena: sluggish.
Table two:
| Phosphoric acid concentration % | Terminal point pH | Weight yield % | Activeconstituents u/mg | Moisture % | Residue % | Residual solvent % |
| 10 | 6.0 | 70.3 | 769/815 | 5.6 | 0.7 | Do not detect |
Press European patent RU2190410 embodiment, as reaction medium, under 4～7 ℃, carry out acidification reaction, control reaction end pH6.4～6.6 through ortho-phosphoric acid solution with water.Experimental data sees Table three.
Experimental phenomena: easily separate out crystal in the reaction process, operation is difficulty.
Table three:
| Temperature of reaction ℃ | Terminal point pH | Weight yield % | Activeconstituents u/mg | Moisture % | Residue % | Residual solvent % |
| 6 | 6.5 | 68.5 | 774/819 | 5.5 | 0.6 | Do not detect |
1, the present invention adopts erythromycin salt (Matachrom, erythromycin lactate) preparation phosphoric acid erythromycin, control transforms extraction temperature at 10～30 ℃, transforming under the identical condition of extraction pH, transforms extraction and carries out easily, emulsification is little, erythromycin unit's height in the extraction liquid.During the concentration of control same reaction temperature, reaction end pH, phosphoric acid solution, the weight yield of prepared phosphoric acid erythromycin and activeconstituents are all than U.S. Pat 3276956 and European patent RU2190410 height in selected conversion extraction temperature scope.Experimental data sees Table four.
Table four:
2, the present invention adopts erythromycin salt (Matachrom, erythromycin lactate) preparation phosphoric acid erythromycin, and control transforms extraction pH8.0～13, and under identical conversion extraction temperature, emulsification is little, erythromycin unit's height in the extraction liquid.When controlling the concentration of identical temperature of reaction, reaction end pH, phosphoric acid solution, compare with U.S. Pat 3276956 and European patent RU2190410, the weight yield and the activeconstituents of prepared phosphoric acid erythromycin are all better in selected conversion extraction PH scope.Experimental data sees Table five.
Table five:
3, the present invention adopts erythromycin salt (Matachrom, erythromycin lactate) preparation phosphoric acid erythromycin, be controlled to 10～50 ℃ of reactant salt temperature, get same approving and forwarding extraction liquid, drip the phosphoric acid solution of same concentrations, when controlling identical reaction end pH, in selected salify temperature range, overcome in operating process that temperature is low easily separates out the shortcoming that crystal influences yield and the too high destructible activeconstituents of temperature, the weight yield of prepared phosphoric acid erythromycin and activeconstituents are all than U.S. Pat 3276956 and European patent RU2190410 height.See the following form six.
Table six:
4, the present invention adopts erythromycin salt (Matachrom, erythromycin lactate) preparation phosphoric acid erythromycin, be controlled to reactant salt terminal point pH4.0～5.8, get same approving and forwarding extraction liquid, drip the phosphoric acid solution of same concentrations, under same temperature of reaction, can control reaction end more accurately with the method that is controlled to reactant salt pH, the prepared weight yield that obtains phosphoric acid erythromycin is all better than U.S. Pat 3276956 and European patent RU2190410 with activeconstituents.Experimental data sees Table seven.
Table seven:
5, the present invention adopts erythromycin salt (Matachrom, erythromycin lactate) preparation phosphoric acid erythromycin, the concentration 15%～60% of control phosphoric acid solution, get same approving and forwarding extraction liquid, under same temperature of reaction, when controlling identical terminal point pH, in selected phosphoric acid solution concentration range, compare difficult local overacidification, the gum deposit phenomenon of producing with the phosphoric acid of 85% concentration, stir easily, help the control of reaction end, the weight yield of preparation gained phosphoric acid erythromycin is all better than U.S. Pat 3276956 and European patent RU2190410 with activeconstituents.Experimental data sees the following form eight.
Table eight:
6, the present invention adopts erythromycin salt (Matachrom, erythromycin lactate) preparation phosphoric acid erythromycin, transform 23 ℃ of extraction temperature controls, transform extraction pH11.5,35 ℃ of temperature of reaction, terminal point pH4.4, under the condition of phosphoric acid concentration 45%, be carried out to reactant salt in different solvents, the weight yield of phosphoric acid erythromycin is all higher than U.S. Pat 3276956 and European patent RU2190410 with activeconstituents.Experimental data sees the following form nine in detail.
Table nine:
Embodiment
Further set forth the synthetic method for preparing phosphoric acid erythromycin with erythromycin salt below by embodiment.
The equipment that is adopted among the embodiment is commercially available equipment, can both make following product by industry is known with industry standard.Phosphoric acid among the embodiment-n-butyl acetate solution is meant that wherein the per-cent of phosphoric acid is volume percent with phosphoric acid and 60% formulated phosphoric acid of n-butyl acetate.Phosphoric acid in following examples-isobutyl acetate solution; Phosphoric acid-compounded organic solvent solution, compounded organic solvent are the mixture of propyl carbinol, n-butyl acetate and mibk, also as mentioned above.
Embodiment 1, and its preparation method comprises following several steps successively:
1) with organic solvent as extraction agent, utilization is compared, and extracts between water and organic phase solution, obtains being rich in the concentrated solution of extract;
2) with 1) the concentrated organic solution that obtains of step carries out crystallization reaction, obtains crystallisate;
3) with 2) crystallisate that obtains of step is through separating, and water is refining, obtains phosphoric acid erythromycin finished product after the drying;
4) described extraction process is: erythromycin salt is placed C
4-C
6Contain in the double solvents of the organic solvent of hydroxyl or carbonyl and mixture, add water, stir, regulate pH8～13 with alkaline solution, extraction temperature is controlled at 10～30 ℃, divides the phase of anhydrating, and obtains being rich in the organic solution of extract, wherein erythromycin salt is (weight/volume) 1: 15～20 with the ratio of organic solvent, and erythromycin salt is (w/w) 1: 1～5 with the ratio of water;
5) described crystallization processes is: adopt the phosphoric acid acidization to carry out precipitated crystal, promptly in the organic phase solution that is rich in extract that obtains, drip phosphoric acid solution continuously, obtain the crude product of phosphoric acid erythromycin, wherein temperature of reaction is 10～50 ℃, the concentration 15%～60% of phosphoric acid solution, and phosphoric acid solution is the organic solution of phosphoric acid, reaction end pH4～5.8
6) the described crystal of adding makes technology and is: reactant is washed with water, and through separating, drying obtains the finished product of phosphoric acid erythromycin again.
Embodiment 1:
The Matachrom of 12.5g is joined in the mixing solutions of 230ml n-butyl acetate and 60ml water, 23 ℃ of stirrings, add NaOH solution and transfer pH, continuing to stir dissolves Matachrom fully, until reaction solution pH is 11.5, and standing demix is got the n-butyl acetate phase, with saturated NaCl solution dehydrates, obtain extraction liquid, in extraction liquid, add phosphoric acid-n-butyl acetate solution of 2.5ml 45%, maintain the temperature at 35 ℃ in the dropping process, assaying reaction liquid terminal point pH4.4, leave standstill 40min, centrifugal 30min washes reactant with water, separate vacuum filtration, oven drying obtains phosphoric acid erythromycin finished product.
Embodiment 2:
Embodiment 2 and the preparation process of embodiment 1 are basic identical, and different is to prepare phosphoric acid erythromycin with erythromycin lactate, and takes following different solvent and parameter:
The erythromycin lactate of 15.0g is joined in the mixing solutions of 300ml isobutyl acetate and 15ml water, stir, transform extraction temperature and be controlled at 10 ℃, add solution of potassium carbonate again and transfer pH, the pH that transforms extraction liquid is controlled at 8.0, standing demix, the isobutyl acetate phase, with saturated NaCl solution dehydrates, obtain extraction liquid, in extraction liquid, add phosphoric acid-isobutyl acetate solution of 4.2ml 30%, maintain the temperature at 10 ℃ in the dropping process, assaying reaction liquid terminal point pH4.0 obtains phosphoric acid erythromycin with the spouted drying of reaction product.
Embodiment 3:
Embodiment 3 and the preparation process of embodiment 1 are basic identical, and different is to prepare phosphoric acid erythromycin with Matachrom, and takes following different solvent and parameter:
The Matachrom of 20.0g is joined 350ml contain propyl carbinol, in the mixed organic solvents of n-butyl acetate and mibk and the 100ml water, stir, temperature is raised to 30 ℃, add yellow soda ash again and transfer pH, after continuation is stirred Matachrom is dissolved fully, the pH that transforms extraction liquid is controlled at 13.0, after the layering, discard lower floor's water, organic phase obtains extraction liquid with saturated NaCl solution dehydrates, the above-mentioned mixed organic solvents solution that in extraction liquid, adds the phosphoric acid of 13.2ml 15%, maintain the temperature at 25 ℃ in the dropping process, assaying reaction liquid terminal point pH5.8, static 40min, centrifugal 30min, wash reactant with water, separate, oven drying obtains phosphoric acid erythromycin finished product.
Embodiment 4:
Embodiment 4 and the preparation process of embodiment 1 are basic identical, and different is to prepare phosphoric acid erythromycin with erythromycin lactate, and takes following different solvent and parameter:
The erythromycin lactate of 25.0g is joined 375ml contain propyl carbinol, in the mixed organic solvents of n-butyl acetate and mibk mixed solvent and 100ml water, stir, transform extraction temperature and be controlled at 15 ℃, add potassium hydroxide solution again and transfer pH, the pH that transforms extraction liquid is controlled at 10.0, standing demix, discard lower floor's water, organic phase with saturated NaCl solution dehydrates after, obtain extraction liquid, in extraction liquid, add the above-mentioned mixed organic solvents solution of the phosphoric acid of 4.5ml 40%, maintain the temperature at 50 ℃ in the dropping process, assaying reaction liquid terminal point pH 5.2, spouted drying obtains phosphoric acid erythromycin finished product.
Embodiment 5:
Embodiment 5 and the preparation process of embodiment 1 are basic identical, and different is to prepare phosphoric acid erythromycin with Matachrom, and takes following different solvent and parameter:
The Matachrom of 50g is joined in 800ml isobutyl acetate and the 100ml water, stir down at 25 ℃, add NaOH solution and transfer pH, continuing to stir dissolves erythromycin lactate fully, until reaction solution pH is 9.0, and standing demix is got the isobutyl acetate phase, with saturated NaCl solution dehydrates, obtain extraction liquid, in extraction liquid, add phosphoric acid-isobutyl acetate solution of 7.5ml 60%, maintain the temperature at 45 ℃ in the dropping process, assaying reaction liquid terminal point pH4.2, leave standstill 40min, centrifugal 30min washes reactant with water and removes residual, separate vacuum filtration, drying obtains phosphoric acid erythromycin finished product.
Embodiment 6:
Embodiment 6 and the preparation process of embodiment 1 are basic identical, and different is to prepare phosphoric acid erythromycin with erythromycin lactate, and takes following different solvent and parameter:
The erythromycin lactate of 51g is joined 1000ml contain propyl carbinol, in n-butyl acetate and mibk mixed solvent and the 150ml water, stir down at 20 ℃, add NaOH solution and transfer pH, continuing to stir dissolves erythromycin lactate fully, until reaction solution pH is 12.0, and standing demix is got organic phase, with saturated NaCl solution dehydrates, obtain extraction liquid, in extraction liquid, add the phosphoric acid solution of 12.5ml 35%, maintain the temperature at 20 ℃ in the dropping process, assaying reaction liquid terminal point pH5.5, leave standstill 40min, centrifugal 30min washes reactant with water and removes residual, separate vacuum filtration, drying obtains phosphoric acid erythromycin finished product.
Claims (10)
1. prepare the method for phosphoric acid erythromycin with erythromycin salt, it is characterized in that: erythromycin salt is placed C
4-C
6Contain in the organic solvent of the organic solvent of hydroxyl or carbonyl or its mixture, add water, stir, add alkaline solution and regulate the pH value, control transforms extraction temperature, through stirring erythromycin salt is dissolved in the organic phase fully, divides the phase of anhydrating then, in organic phase, add phosphoric acid solution, regulate the pH value with the mode of continuous dropping phosphoric acid solution, carry out crystallization reaction by control phosphoric acid solution concentration with erythromycin organic phase temperature of reaction, add crystal's system, finally after separating drying, obtain phosphoric acid erythromycin finished product.
2. according to claim 1ly prepare the method for phosphoric acid erythromycin with erythromycin salt, it is characterized in that: described erythromycin salt is an erythromycin lactate, Matachrom.
3. according to claim 1ly prepare the method for phosphoric acid erythromycin, it is characterized in that: described C with erythromycin salt
4-C
6The organic solvent that contains hydroxyl or carbonyl is a n-butyl acetate, isobutyl acetate; The organic solvent of described mixture is the compounded organic solvent of propyl carbinol, n-butyl acetate and mibk.
4. according to claim 1ly prepare the method for phosphoric acid erythromycin with erythromycin salt, it is characterized in that: the preparation of described phosphoric acid solution is to prepare with the phosphoric acid solvent identical with reaction medium, and concentration of phosphoric acid is 15%～60%; Reaction medium is that erythromycin is dissolved in C
4-C
6A kind of or the water that contains the organic solvent of hydroxyl, carbonyl.
5. according to claim 1ly prepare the method for phosphoric acid erythromycin with erythromycin salt, it is characterized in that: described adding alkaline solution is regulated and transformed extraction pH value is 8～13, and described conversion extraction temperature remains on 10 ℃～30 ℃.
6. according to claim 1ly prepare the method for phosphoric acid erythromycin with erythromycin salt, it is characterized in that: described erythromycin salt is weight/volume 1: 15～20 with the ratio of organic solvent; Described erythromycin salt is weight/volume 1: 1～5 with the ratio of water.
7. according to claim 1ly prepare the method for phosphoric acid erythromycin, it is characterized in that with erythromycin salt: described control phosphoric acid solution concentration and with erythromycin organic phase temperature of reaction be 10 ℃～50 ℃.
8. according to claim 1ly prepare the method for phosphoric acid erythromycin with erythromycin salt, it is characterized in that: described its terminal point of phosphoric acid erythromycin finished product pH is 4～5.8.
9. according to claim 1ly prepare the method for phosphoric acid erythromycin with erythromycin salt, it is characterized in that: described alkaline solution is a salt of wormwood, yellow soda ash, the aqueous solution of potassium hydroxide or sodium hydroxide.
10. according to claim 1ly prepare the method for phosphoric acid erythromycin with erythromycin salt, its method is: it comprises following several steps successively;
1) with organic solvent as extraction agent, utilization is compared, and extracts between water and organic phase solution, obtains being rich in the concentrated solution of extract;
2) with 1) the concentrated organic solution that obtains of step carries out crystallization reaction, obtains crystallisate;
3) with 2) crystallisate that obtains of step is through separating, and water is refining, obtains phosphoric acid erythromycin finished product after the drying;
4) described extraction process is: erythromycin salt is placed C
4-C
6Contain in the double solvents of the organic solvent of hydroxyl or carbonyl and mixture, add water, stir, regulate pH8～13 with alkaline solution, extraction temperature is controlled at 10～30 ℃, divides the phase of anhydrating, and obtains being rich in the organic solution of extract, wherein erythromycin salt is weight/volume 1: 15～20 with the ratio of organic solvent, and erythromycin salt is weight/volume 1: 1～5 with the ratio of water;
5) described crystallization processes is: adopt the phosphoric acid acidization to carry out precipitated crystal, promptly in the organic phase solution that is rich in extract that obtains, drip phosphoric acid solution continuously, obtain the crude product of phosphoric acid erythromycin, wherein temperature of reaction is 10～50 ℃, the concentration 15%～60% of phosphoric acid solution, phosphoric acid solution are the organic solution of phosphoric acid, reaction end pH4～5.8;
6) the described crystal of adding makes technology and is: reactant is washed with water, and through separating, drying obtains the finished product of phosphoric acid erythromycin again.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100417585A CN100400545C (en) | 2006-02-07 | 2006-02-07 | Method for preparing phosphate eritrocina using eritrocina salt |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100417585A CN100400545C (en) | 2006-02-07 | 2006-02-07 | Method for preparing phosphate eritrocina using eritrocina salt |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1807442A CN1807442A (en) | 2006-07-26 |
| CN100400545C true CN100400545C (en) | 2008-07-09 |
Family
ID=36839553
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2006100417585A Active CN100400545C (en) | 2006-02-07 | 2006-02-07 | Method for preparing phosphate eritrocina using eritrocina salt |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100400545C (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3276956A (en) * | 1963-05-31 | 1966-10-04 | Abbott Lab | Treating infections in poultry caused by pleuropneumoniia-like organisms with erythromycin phosphate |
| RU2190410C1 (en) * | 2001-06-18 | 2002-10-10 | Акционерное Курганское общество медицинских препаратов и изделий "Синтез" | Method of injection form of erythromycin phosphate preparing |
-
2006
- 2006-02-07 CN CNB2006100417585A patent/CN100400545C/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3276956A (en) * | 1963-05-31 | 1966-10-04 | Abbott Lab | Treating infections in poultry caused by pleuropneumoniia-like organisms with erythromycin phosphate |
| RU2190410C1 (en) * | 2001-06-18 | 2002-10-10 | Акционерное Курганское общество медицинских препаратов и изделий "Синтез" | Method of injection form of erythromycin phosphate preparing |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1807442A (en) | 2006-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI453015B (en) | Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof | |
| CN100999522B (en) | Preparation process of palmatine | |
| DE3500179A1 (en) | ACETYLERYTHROMYCINSTEARATE, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCT CONTAINING THIS | |
| WO2017128941A1 (en) | Bamboo leaf extract and preparation method and use thereof | |
| EP3406619B1 (en) | Method and intermediate for preparing tulathromycin | |
| JP2016515547A (en) | Triazine compounds with anti-chicken coccidiosis | |
| CN1269803A (en) | 6,9-bridged erythromycin derivatives | |
| CN101402612A (en) | Synthesis of quinocetone | |
| CN100400545C (en) | Method for preparing phosphate eritrocina using eritrocina salt | |
| EP0133971B1 (en) | Antibiotic, its preparation and its use | |
| CN100434435C (en) | Method for preparing phosphate eritrocina using eritrocina | |
| CN104288098B (en) | A kind of preparation method of decoquinate ester solution | |
| EP0112517A1 (en) | Polyether compounds | |
| CN108929253B (en) | Pleuromutilin compound and preparation method and application thereof | |
| CN103421063B (en) | A kind of method of synthesizing morphine-6-β-D-Glucose aldehydic acid glycosides | |
| CN1273446C (en) | Bearing-resisting compound and preparing method | |
| CN107935848B (en) | Hexaalizarin derivative and preparation method and application thereof | |
| DE1543769A1 (en) | Process for the production of flavan derivatives | |
| CN105189459B (en) | Compound and its manufacture method, with and application thereof | |
| DE60115851T2 (en) | ANTI-INFECTANTS WHICH ARE USEFUL AGAINST MULTIPLE DRUGS RESISTANT BACTERIAL STRAINS | |
| CN107158114A (en) | A kind of acetylation Morinda officinalis water extract and its preparation method and application | |
| CN115925772B (en) | Synthesis method of tilmicosin | |
| CN102631360A (en) | Application of oleanane glycoside to preparation of drugs for treating and/or preventing schistosomiasis | |
| DE2621615C3 (en) | Dihydromocimycin, its salts, process for its preparation and its use as a feed additive | |
| CN102558076B (en) | 1-oxygen-2-hydroxylmethyl-3-(1-ethoxyl)-quinoxaline, as well as preparation method and application of 1-oxygen-2-hydroxylmethyl-3-(1-ethoxyl)-quinoxaline |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Method for preparing phosphate eritrocina using eritrocina salt Effective date of registration: 20150929 Granted publication date: 20080709 Pledgee: Shaanxi Qin Nong rural commercial bank Limited by Share Ltd Pledgor: Xi'an Lijun Pharmaceutical LLC Registration number: 2015990000836 |
|
| PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20200710 Granted publication date: 20080709 Pledgee: Shaanxi Qin Nong rural commercial bank Limited by Share Ltd Pledgor: Xi'an Lijun Pharmaceutical Co.,Ltd. Registration number: 2015990000836 |